Finance
Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range.
B
Bloomberg
April 30, 2026·1 min read
Image: Bloomberg
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range.
Original article
Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Published by Bloomberg